A high calcium diet containing nonfat dry milk reduces weight gain and associated adipose tissue inflammation in diet-induced obese mice when compared to high calcium alone by Thomas, Anthony P et al.
RESEARCH Open Access
A high calcium diet containing nonfat dry milk
reduces weight gain and associated adipose
tissue inflammation in diet-induced obese mice
when compared to high calcium alone
Anthony P Thomas
1†, Tamara N Dunn
1†, Josephine B Drayton
2, Pieter J Oort
3 and Sean H Adams
1,3*
Abstract
Background: High dietary calcium (Ca) is reported to have anti-obesity and anti-inflammatory properties. Evidence
for these properties of dietary Ca in animal models of polygenic obesity have been confounded by the inclusion of
dairy food components in experimental diets; thus, effect of Ca per se could not be deciphered. Furthermore,
potential anti-inflammatory actions of Ca in vivo could not be dissociated from reduced adiposity.
Methods: We characterized adiposity along with metabolic and inflammatory phenotypes in diet-induced obese
(DIO) mice fed 1 of 3 high fat diets (45% energy) for 12 wk: control (n = 29), high-Ca (n = 30), or high-Ca + nonfat
dry milk (NFDM) (n = 30).
Results: Mice fed high-Ca + NFDM had reduced body weight and adiposity compared to high-Ca mice (P <
0.001). Surprisingly, the high-Ca mice had increased adiposity compared to lower-Ca controls (P < 0.001).
Hyperphagia and increased feed efficiency contributed to obesity development in high-Ca mice, in contrast to
NFDM mice that displayed significantly reduced weight gain despite higher energy intake compared to controls
(P < 0.001). mRNA markers of macrophages (e.g., CD68, CD11d) strongly correlated with body weight in all diet
treatment groups, and most treatment differences in WAT inflammatory factor mRNA abundances were lost when
controlling for body weight gain as a covariate.
Conclusions: The results indicate that high dietary Ca is not sufficient to dampen obesity-related phenotypes in
DIO mice, and in fact exacerbates weight gain and hyperphagia. The data further suggest that putative anti-obesity
properties of dairy emanate from food components beyond Ca.
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Background
Epidemiological or cross-sectional studies in human popu-
lations support an inverse relationship between dietary cal-
cium (Ca) and dairy food consumption with obesity.
Several clinical weight loss intervention studies that
included high-Ca or dairy foods indicated a positive effect
on body fat loss [1,2], but this has not been universally
observed [3], suggesting that these effects are context-
specific (e.g., dependent upon the specific population, diet-
ary Ca status, type of dairy food, or provision of elemental
C av s .C ai nad a i r ym a t r i x ) .I nc o n t r a s t ,f a tl o s so r
reduced weight gain in response to high-Ca plus dairy pro-
tein in rodent obesity models has been consistently
reported [4-7]. The mechanisms underlying the metabolic
effects of Ca and dairy foods to reduce adiposity remain to
be elucidated. Increased fecal fat loss due to the formation
of indigestible Ca soaps in the gastrointestinal tract has
been proposed as a possible mechanism by which high
dietary Ca reduces adiposity [8]. Research from one group
has provided evidence in vitro and in the aP2-agouti trans-
genic mouse model of diet-induced obesity for a potential
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any medium, provided the original work is properly cited.role of the calcitrophic hormone 1,25-dihydroxyvitamin D
(calcitriol) in promoting adipocyte lipogenesis and inhibit-
ing lipolysis, thus encouraging adipocyte lipid accumula-
tion [9-11]. According to this model, increasing dietary Ca
would suppress circulating calcitriol, discouraging energy
storage and white adipose tissue (WAT) expansion.
Dietary Ca may also impact inflammatory phenotypes
associated with obesity. Chronic inflammation of WAT,
especially in visceral depots, contributes to the pathogen-
esis of obesity-related insulin resistance [12-14], and WAT
macrophages are a prominent source of pro-inflammatory
cytokine production [15-18]. Calcitriol increased pro-
inflammatory cytokine gene expression and secretion from
cultured adipocytes and macrophages, and this response
was dependent on intracellular Ca-provoked reactive
oxygen species (ROS) generation; co-culture of both cell
types increased gene expression and protein secretion of
pro-inflammatory cytokines, which was further enhanced
by calcitriol [19]. In vivo evidence for anti-inflammatory
properties of high dietary Ca was demonstrated in the
aP2-agouti transgenic mouse obesity model in which
increased dietary Ca was associated with reduced plasma
calcitriol [20,21]. Despite a potential mechanism for direct
anti-inflammatory properties of dietary Ca through sup-
pression of circulating calcitriol, reduced inflammation
could not be dissociated from lower body weight and
adiposity in studies of the aP2-agouti transgenic mice.
Furthermore, one cannot exclude a confounding effect of
adipose agouti protein overexpression on these pheno-
types, or possible effects of agouti expression in macro-
phages since the aP2 promoter can be activated in both
macrophages and fat cells. Thus, further research is neces-
sary to confirm potential anti-inflammatory properties of
high dietary Ca and/or dairy in polygenic obesity models
while controlling for body weight and adiposity changes
typically observed in animals fed these diets.
Additional bioactive components of dairy foods (e.g.
branched chain amino acids, peptide fragments with
angiotensin converting enzyme (ACE)-inhibitory proper-
ties) might contribute to anti-obesity/anti-inflammatory
outcomes, since high Ca in a dairy matrix yielded greater
effects vs. elemental Ca alone in aP2-agouti mice [22].
Studies demonstrating an anti-obesity effect of increased
dietary Ca in polygenic obesity models have been only in
t h ec o n t e x to fn o n f a td r ym i l k( N F D M )o rw h e yp r o v i d -
ing all dietary protein [4,6,7]. Thus, comparing high Ca
diet in matrices containing differing protein and carbohy-
drate sources (dairy and non-dairy) is of interest to
understand if non-Ca factors in dairy foods could play a
role in regulation of metabolism and obesity-associated
inflammation.
To address whether dietary Ca can impact obesity phe-
notypes and to understand if putative anti-inflammatory
effects of high-Ca or dairy-based diets are yoked to body
weight, we investigated the potential anti-obesity and anti-
inflammatory effects of high dietary Ca in a well-charac-
terized polygenic mouse model of diet-induced obesity
(DIO): male C57BL/6J mice display susceptibility to diet-
induced obesity and glucose intolerance when fed a high
fat diet [23] and we have previously described obesity with
associated inflammation and impaired glucose homeosta-
sis when feeding these mice a diet providing 45% energy
as fat (with soy- and sucrose/cornstarch-based protein and
carbohydrate sources, respectively) for up to 12 wk [24].
We hypothesized that independent of differences in body
weight gain, DIO mice fed high-Ca would have reduced
body weight, decreased adiposity, and improved metabolic
and inflammatory phenotypes compared to control mice
fed a lower Ca diet. Our study design also enabled a com-
parison of metabolic and inflammatory outcomes in high-
Ca DIO mice relative to animals fed high-Ca in a dairy




All mouse protocols were approved by the University of
California at Davis Institutional Animal Care and Use
Committee according to Animal Welfare Act guidelines.
Four-wk-old male C57BL/6J mice were purchased from
the Jackson Laboratory and individually housed under
standard temperature (20-22°C) and light/dark cycle
(12 h:12 h) conditions in a pathogen-free facility. Individu-
ally-housed mice were fed Picolab
® Mouse Diet 20 (Purina
LabDiet
®) providing ~22, ~22, and ~56% energy as protein,
fat, and carbohydrate, respectively, for a 1 wk acclimation
period. Weight matched mice were randomly assigned to
purified experimental diets containing 45% energy as fat
(Table 1) for 12 wk. Treatment groups were: soy protein-
based control (0.5% Ca, n = 29; Control), soy protein-based
high-Ca (1.5% Ca, n = 30; high-Ca), or high-Ca in the con-
text of nonfat dry milk protein and carbohydrates (1.5%
Ca, n = 30; high-Ca + NFDM). In the case of the NFDM
diet, to ensure equal macronutrient energy contribution
compared to the other diets while maintaining a dairy
nutrient matrix, protein (casein and whey-derived lactalbu-
min) and carbohydrate (galactose + glucose, the compo-
nents of lactose) were added. Ca phosphate (CaPO4)w a s
added to the soy-protein based diets to match that natu-
rally-derived from NFDM (to control for type of dietary
Ca), with Ca carbonate providing all additional Ca to the
experimental diets as typically used in rodent studies com-
paring different dietary Ca. Cellulose content was adjusted
accordingly to account for added Ca in the high-Ca diets
to ensure matched macro and micronutrient content of
diets, and amounts of fiber are all within the normal range
used in purified mouse diets. The control diet and 12 wk
timeframe were previously shown to elicit obesity,
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Page 2 of 11increased WAT inflammation, and insulin resistance in
this model [24]. Mice were given free access to food and
water with body weight and food intake (plus spillage)
measurements made every 2-3 d. Fecal collections over 48
h were made on a subset of randomly chosen mice (n =
10/group) at wk 10. Feces were weighed and stored at -80°
C until bomb calorimetry was performed by Covance
Laboratories. Percent fecal energy loss was calculated from
each animal’s 48 h fecal energy loss and energy consump-
tion. Glucose tolerance tests were administered on a subset
of randomly chosen mice (n = 15-16/group) as described
elsewhere [24]. At wk 12, mice were briefly food-deprived
prior to tissue and blood collection as described in detail
[24].
Total RNA Isolation and Gene Expression Analyses
Total RNA was isolated from whole retroperitoneal (RP)
fat pads, cDNA was prepared, and 384-well quantitative
PCR utilizing gene-specific Taqman
® primers and FAM-
MGB labeled probes (Additional file 1; Assays-on-
Demand
®, Applied Biosystems) was conducted as pre-
viously described in detail [24].
Plasma Cytokines/Chemokines, Glucose, Insulin, and
Calcitriol
Plasma cytokines/chemokines were measured according
to manufacturer’s instructions in duplicate for plasma
samples (20 μL/reaction; n = 15/group) using a Milli-
plex
® MAP Mouse Cytokine/Chemokine Kit (Millipore)
on a Bio-Plex system with xMAP
® Luminex
® technol-
ogy utilizing Bio-Plex Manager version 5.0 software
(Bio-Rad). Plasma glucose was measured according to
manufacturer’s instructions in duplicate (5 μL/reaction)
with the Glucose (HK) Assay Kit (Sigma). Plasma insulin
was measured according to manufacturer’s instructions
in duplicate (5 μL/reaction) with an Ultra Sensitive
Table 1 Mouse Diet Composition*
Diet [product code]
Control (0.5% Ca) [TD.08511] High-Ca (1.5% Ca) [TD.09068] High-Ca + NFDM [TD.09069]
Ingredients (g/kg)
Isolated Soy Protein 195 195 0
Milk Powder, skim 0 0 400
Casein 0 0 29.5
Lactalbumin 0 0 7.5
DL-Methionine 2.34 2.34 1.24
L-Cystine 1 1 0.55
Sucrose 190 190 0
Galactose 0 0 18.5
Dextrose, monohydrate 0 0 20.29
Corn Starch 87.99 87.99 0
Maltodextrin 200 200 200
Cellulose 50 25.25 40
Lard 205 205 205
Soybean Oil 20 20 20
Mineral Mix w/o Ca & P (98057) 17 17 17
Calcium Phosphate, dibasic 14.5 14.5 0
Calcium Carbonate 1.1 26 24.5
Vitamin Mix, AIN-93-VX (94047) 12.7 12.7 12.7
Choline Bitartrate 3.2 3.2 3.2
TBHQ, antioxidant 0.02 0.02 0.02
Macronutrients (% by weight)
Protein 17.3 17.3 17.2
Carbohydrate 47.4 47.4 44.4
Fat 23.4 23.4 22.8
Macronutrients (% kcal)
Protein 14.7 14.7 15.2
Carbohydrate 40.4 40.4 39.3
Fat 44.9 44.9 45.4
KJ/g 19.7 19.7 18.8
*Diets formulated and produced by Harlan Teklad. NFDM, nonfat dry milk.
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(100 μL pooled plasma from 3 mice/reaction) calcitriol
levels (n = 8-9/group) were measured by 1,25-dihydrox-
yvitamin D radioimmunoassay (Immunodiagnostic Sys-
tems Inc.) according to manufacturer’s instructions.
Western Blot Analysis of Brown Adipose Tissue
Uncoupling Protein 1 (UCP1)
Whole intrascapular brown adipose tissue (BAT) pads
(n = 8/group) were homogenized in M-PER
® Reagent
(200 μL/100 g tissue) in the presence of HALT Protease
and Phosphatase Inhibitor Cocktail + 0.5 M EDTA
(Pierce). Proteins (25 μg) were separated using a 12% Bis-
Tris Criterion™ XT Precast Gel (Bio-Rad) and NuPAGE
®
MOPS SDS Running Buffer (Invitrogen) at 200 V for
~ 1 h. Proteins were transferred at 30 V for 1 h to an
Immobilon™ polyvinylidene fluoride membrane (Milli-
pore), blocked overnight at 4°C with 5% nonfat dry milk in
PBS with 0.1% Tween 20 (PBS-T) and incubated with rab-
bit polyclonal anti-UCP1 primary antibody (1:5000 dilu-
tion; U6382, Sigma) at room temperature for 1 h followed
by 3 × 15 min washes in PBS-T. The membrane was incu-
bated with HRP-conjugated goat anti-mouse IgG second-
ary antibody (1:10000 dilution; 1031-05, Southern Biotech)
at room temperature for 1 h followed by 3 × 5-15 min
washes in PBS-T. Antibody binding was visualized and
relative protein levels were quantified using chemilumines-
cence (Immun-Star™ WesternC™ Chemiluminescent Kit,
Bio-Rad) and ChemiDoc™ XRS+ Imaging System (Bio-
Rad). Membrane was stripped using Restore™ PLUS Wes-
tern Blot Stripping Buffer (Pierce) and reprobed using a
pig monoclonal anti-glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) antibody (1:1000 dilution; NB300-221,
Novus Biologicals) to control for protein loading.
Liver Triglycerides
Liver lipid extraction (n = 10/group) was performed uti-
lizing a modified Folch method [25]. Briefly, approxi-
mately 100 mg of liver was homogenized in a 2:1 (v:v)
chloroform:methanol solution (20 μL/mg tissue) followed
by separation of the organic phase and dehydration by
speed-vac prior to being reconstituted in 1 mL isopropa-
nol. Triglyceride content of lipid extracts was measured
using an enzymatic assay kit (TR0100, Sigma) according
to manufacture’s instructions.
Statistical Analysis
A one-way ANOVA with Newman-Keuls Multiple Com-
parison post hoc test was used for three-group comparisons
(Prism v. 4.0, Graphpad). Two-way repeated measures
ANOVA was used to assess effects of diet, time, and diet ×
time interactions on body weight gain and cumulative
energy intake. Pearson’s correlation coefficient was deter-
mined to assess bivariate relationships between body
weight and CD68/CD11d mRNA abundance. In order to
assess the contribution of differences in weight gain on
markers of RP-WAT macrophage infiltration and inflam-
mation, and to assess the impact of food intake on weight
gain, ANCOVA was used to compare the group means of
the log transformed outcome variables controlling for the
indicated covariate (SAS for Windows Release 9.2). Data
are expressed as mean ± SEM and differences considered
to be statistically significant at P ≤ 0.05.
Results
Body Weight Gain, Cumulative Energy Intake, and Feed
Efficiency
Body weight gain and terminal body weights were signifi-
cantly reduced in mice fed high-Ca + NFDM relative to
controls (Figure 1A). Contrary to our expectations, mice
fed high-Ca were significantly heavier than controls
(Figure 1A). There was a significant diet × time interaction
on body weight gain (P < 0.0001). Compared to controls,
mean body weight was heavier starting at d 27 (P <0 . 0 5 )
and lower starting at d 36 (P < 0.01) of diet onward for
mice fed high-Ca or high-Ca + NFDM, respectively. Mice
fed high-Ca + NFDM weighed significantly less than mice
fed high-Ca starting at d 17 (P < 0.05) of diet onward.
Increased cumulative energy intake in mice fed high-Ca
compared to both controls and high-Ca + NFDM fed mice
(Figure 1B) may account for increased body weight gain in
this group, in contrast to high-Ca + NFDM mice that dis-
played greater cumulative energy intake compared to con-
trols (Figure 1B) despite significantly lower body weight
gain. Terminal body weights were not significantly different
between mice fed high-Ca compared to controls when con-
trolling for food intake (ANCOVA), indicating that intake
explained much of the obesity in the high-Ca group; in
contrast, when controlling for food intake, weight remained
significantly reduced in mice fed high-Ca + NFDM com-
pared to controls or mice fed high-Ca (P < 0.0001). There
was a significant diet × time interaction on cumulative
energy intake (P < 0.0001), with mean cumulative energy
intake higher starting at d 13 (P < 0.05) and at d 57 (P <
0.05) of diet onward for mice fed high-Ca or high-Ca +
NFDM, respectively, compared to controls. Feed efficiency
(mg weight gain/kJ consumed) in mice fed high-Ca +
NFDM was reduced (2.3 + 0.1) compared to controls
(3.5 ± 0.1; P <0 . 0 0 1 )a n dh i g h - C am i c e( 3 . 8±0 . 1 ;P <
0.001); the latter group had increased feed efficiency com-
pared to controls (P <0 . 0 1 ) .
To determine the potential mechanisms underlying the
marked differences in feed efficiencies, we examined mar-
kers of BAT activation considering the importance of this
tissue to thermogenesis in mice. BAT weight was signifi-
cantly increased in mice fed high-Ca compared to both
controls and high-Ca + NFDM fed mice (Table 2). UCP1
protein content of BAT was increased to 1.7 fold of
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tional file 2). Another factor potentially contributing to
differences in feed efficiency is net energy absorption in
the gut. There were significant diet-related differences in
fecal output and fecal energy density (Additional file 3),
and energy loss in the feces (as a % of energy intake) was
significantly decreased and increased in mice fed high-Ca
and high-Ca + NFDM, respectively (Additional file 3).
Increased energy consumption coupled to reduced fecal
energy loss resulted in significantly increased net metabo-
lizable energy (in kJ/d) in mice fed high-Ca (66.2 ± 1.8;
P < 0.001) compared to controls (48.1 ± 1.3) and high-
Ca + NFDM mice (47.0 ± 1.4).
Body Composition and Metabolic Phenotypes
Absolute weights of retroperitoneal (RP), epididymal (EPI),
and subcutaneous (SC) fat pads were all significantly lower
in mice fed high-Ca + NFDM compared to controls and
mice fed high-Ca (Figure 2A), which was reflected in
reduced total % body fat (Figure 2B). Weights of EPI and
SC fat pads were significantly heavier in high-Ca mice
compared to controls (Figure 2A), but total % body fat
was not different between these groups (Figure 2B). Liver
weights were significantly heavier in high-Ca mice com-
pared to both controls and mice fed high-Ca + NFDM
(Table 2); the latter two groups did not differ significantly.
This corresponded to increased liver triglycerides (mg/g)
in mice fed high-Ca (98.4 ± 16.5) compared to controls
(59.1 ± 9.9; P < 0.05) and high-Ca + NFDM mice (28.1 ±
10.1; P < 0.01).
Mice fed high-Ca + NFDM had improved glucose toler-
ance (Figure 3A) with significantly reduced glucose area
under the curve compared to controls and mice fed high-
Ca (Figure 3B). Postabsorptive plasma glucose concentra-
tions (mmol/L) measured at the time of tissue collection
was significantly higher in mice fed high-Ca (20.6 ± 0.6;
P < 0.001) and lower in high-Ca + NFDM fed mice (16.2 ±
0.4; P < 0.01), compared to controls (18.2 ± 0.4). Postab-
sorptive plasma insulin levels (pmol/L) followed the same
trend: significantly higher in mice fed high-Ca (225.8 ±
7.7; P < 0.001) and significantly lower in mice fed high-
Ca + NFDM (35.9 ± 3.5; P < 0.01) compared to controls
(100.3 ± 7.75).
Dietary Ca-associated changes in expression of WAT
fatty acid synthase (FAS) and interleukin 15 (IL-15) may
regulate lipid accumulation, and shifts in uncoupling pro-
tein 2 (UCP2) could play a role in mitochondrial function
and reactive oxygen species (ROS) generation [26]. FAS
mRNA abundance in RP-WAT was not significantly dif-
ferent among diet treatment groups (Table 3); RP-WAT
mRNA abundance of UCP2 was significantly decreased in
mice fed high-Ca and high-Ca + NFDM fed mice com-
pared to controls (Table 3), and this reduction was greater
in mice fed high-Ca. mRNA abundance of IL-15 in RP-
WAT was significantly decreased in mice fed high-Ca
compared to controls (Table 3). IL-15 mRNA expression
does not necessarily coincide with protein secretion [27]
and skeletal muscle is the major site of IL-15 mRNA tran-
scription and probably secretion [28,29]. We noted that
plasma IL-15 levels were increased, although highly vari-
able and not statistically significant, in mice fed high-Ca +
NFDM compared to both controls and mice fed high-Ca
(Table 4).
Inflammatory Phenotypes and Plasma Calcitriol
A suite of genes typically associated with obesity-
induced WAT macrophage infiltration, inflammation,
and hypoxic stress were surveyed to determine if dietary
Ca or dairy reduce these parameters in DIO mice. We
have previously measured this panel of markers and
found them to be sensitive to DIO in this model [24].









































































Figure 1 Body weights (A) and cumulative energy intake (B) in
DIO mice fed 0.5% Ca (Control), 1.5% Ca (High-Ca), or 1.5% Ca
+ nonfat dry milk (High-Ca + NFDM). Values are means ± SE, n =
29 (Control) or 30/treatment. Some error bars are within symbols.
Treatments with different letters are significantly different (P < 0.05).
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surface antigen CD68 was increased to ~200% and
decreased to ~71% of control values in mice fed high-Ca
and high-Ca + NFDM fed mice, respectively (Table 3).
We have previously shown CD11d (leukocyte exclusive
Table 2 Tissue weights in diet induced obese mice fed 0.5% Ca (Control), 1.5% Ca (High-Ca), or 1.5% Ca + nonfat dry
milk (High-Ca + NFDM)
1
Diet
Tissue Control High-Ca High-Ca + NFDM
Liver (g) 1.2 ± 0.03
a 1.7 ± 0.07
b 1.1 ± 0.02
a, c
Liver (% body weight) 3.5 ± 0.05
a 4.1 ± 0.12
b 3.7 ± 0.06
a, c
Gastrocnemius muscles (mg) 301 ± 3.6
a 311 ± 4.2
b 288 ± 2.9
c
Gastrocnemius muscles (% body weight) 0.9 + 0.01
a 0.8 ± 0.02
b 1.0 ± 0.01
c
Brown adipose tissue (mg) 176 ± 8.3
a 299 ± 12.1
b 98 ± 4.1
c
Brown adipose tissue (% body weight) 0.5 ± 0.02
a 0.7 ± 0.02
b 0.3 ± 0.01
c
Spleen (mg) 73 ± 1.6
a 86 ± 2.5
b 66 ± 1.8
c
Spleen (% body weight) 0.2 ± 0.00 0.2 ± 0.01 0.2 ± 0.01
1Values are means + SE, n = 29 or 30. Values with different superscript letter are significantly different (P < 0.05).













































































Figure 2 Absolute (A) and relative (B) WAT depot weights in DIO
mice fed 0.5% Ca (Control), 1.5% Ca (High-Ca), or 1.5% Ca +
nonfat dry milk (High-Ca + NFDM).V a l u e sa r em e a n s±S E ,n =2 9
(Control) or 30/treatment. Treatments with different letters are
significantly different (P < 0.05).

















































































Figure 3 Blood glucose concentrations (A) and AUC (B) in DIO
mice fed 0.5% Ca (Control), 1.5% Ca (High-Ca), or 1.5% Ca +
nonfat dry milk (High-Ca + NFDM) following an i.p. glucose
tolerance test. Values are means ± SE, n = 15 or 16/treatment.
Some error bars are within symbols. Treatments with different
letters are significantly different (P < 0.05). Fasting blood glucose
was reduced in mice fed high-Ca + NFDM (11.5 ± 0.3 mmol/L)
compared to DIO controls (12.8 ± 0.4 mmol/L; not significant) and
mice fed high-Ca (14.3 ± 0.8 mmol/L; P < 0.01).
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edly increased obese mice relative to non-obese controls
[24], and this parameter was increased to ~235% and
decreased to ~9% of control values in high-Ca and high-
Ca + NFDM fed mice, respectively (Table 2). Inflamma-
tory markers associated with obese WAT (monocyte che-
moattractant protein 1, MCP-1; tumor necrosis factor a,
TNFa; IL-6) displayed significantly increased and
decreased mRNA abundances in RP-WAT of mice fed
high-Ca and high-Ca + NFDM, respectively, compared to
controls (Table 3). However, hypoxia inducible factor 1a
(HIF-1a) mRNA abundance in RP-WAT was signifi-
cantly decreased in mice fed high-Ca or high-Ca +
NFDM compared to controls (Table 3). RP-WAT mRNA
abundance of IL-10, an anti-inflammatory cytokine, and
found in inflammatory zone 1 (FIZZ-1), a marker of
alternatively activated macrophages, were significantly
increased in mice fed high-Ca compared to both controls
and high-Ca + NFDM fed mice (Table 3). Macrophage-
derived inflammatory cytokines have previously been
shown to increase calcitonin gene related peptide a
(CGRPa) expression in adipocytes and CGRPa may have
anti-inflammatory effects on macrophages [30,31]. This
target is also regulated in neurons and thyroid cells by Ca
status and calcitriol [32,33]. However, RP-WAT mRNA
abundance of CGRPa was not different between diet
treatment groups (Table 3). Despite differences in visc-
eral WAT inflammatory gene expression, differences in
plasma markers associated with inflammation were less
apparent and highly variable (Table 4).
Previous observations that high dietary Ca both with
and without dairy reduce WAT inflammatory gene
expression were confounded by Ca/dairy-associated
reductions in body weight and adiposity [20,21]. To
illustrate the relative influence of body weight on WAT
macrophage accumulation, correlations between body
weight and macrophage marker mRNA levels were
examined (Figure 4). There were significant positive cor-
relations between body weight and the mRNA expres-
sion of CD68 and CD11d in RP-WAT of DIO mice,
regardless of diet treatment, and across a broad range of
body weights (Figure 4). Controlling for body weight as
a covariate, treatment differences in WAT CD68 mRNA
abundances were not significantly different indicating
that CD68-positive macrophage numbers in WAT are
closely yoked to body weight. Controlling for weight
and food intake, differences in CD11d mRNA abun-
dance comparing controls and high-Ca mice were not
statistically significant, but the reduction in CD11d
expression in mice fed high-Ca + NFDM remained
highly significant (P < 0.0001). RP-WAT mRNA abun-
dances of other inflammatory markers (see Table 3)
were not significantly different among diet treatment
groups when controlling for body weight, with the
exceptions of MCP-1 and HIF-1a:M C P - 1r e m a i n e d
significantly decreased in high-Ca + NFDM mice com-
pared to controls (P <0 . 0 0 1 )o rh i g h - C am i c e( P <
0.01), and HIF-1a remained significantly decreased in
mice fed both of the high-Ca diets compared to controls
(P < 0.01).
Calcitriol stimulates inflammatory responses in cul-
tured adipocytes and macrophages [19], and dietary Ca
suppression of circulating calcitriol was observed con-
current with reduced WAT inflammation associated
with obesity development [20,21]. Plasma calcitriol
(pmol/L) was significantly reduced in mice fed high-Ca
(123.9 ± 13.0) compared to controls (187.1 ± 8.6; P <
0.01) and high-Ca + NFDM fed mice (168.9 ± 16.6; P <
0.05), but this was not associated with reductions in
adiposity and inflammation. The more modest reduction
in plasma calcitriol in mice fed high-Ca + NFDM was
not significantly different compared to controls.
Table 3 RP-WAT mRNA levels in diet induced obese mice
fed 0.5% Ca (Control), 1.5% Ca (High-Ca), or 1.5% Ca +
nonfat dry milk (High-Ca + NFDM)
1
Diet
Gene Control High-Ca High-Ca + NFDM
% of Control
Cd68 100.0 ± 8.3
a 213.1 ± 19.5
b 70.9 ± 15.5
a
Itgad (CD11d) 100.0 ± 13.1
a 234.7 ± 28.5
b 8.7 ± 2.5
c
Ccl2 (MCP-1) 100.0 ± 9.2
a 156.2 ± 9.0
b 43.6 ± 4.7
c
Tnf (TNFa) 100.0 ± 4.3
a 154.3 ± 10.5
b 65.4 ± 8.2
c
Il6 100.0 ± 5.2
a 127.1 ± 10.2
b 75.7 ± 4.7
c
Hif1a (HIF-1a) 100.0 ± 8.0
a 82.3 ± 4.1
b 51.2 ± 3.0
c
Il10 100.0 ± 9.0
a 263.6 ± 29.9
b 97.0 ± 16.2
a
Retnla (FIZZ-1) 100.0 ± 5.2
a 174.9 ± 16.3
b 78.9 ± 7.9
a
Calca (CGRPa) 100.0 ± 15.3 75.5 ± 6.7 102.5 ± 13.8
Il15 100.0 ± 3.4
a 68.7 ± 8.4
b 94.6 ± 7.2
a
Fas 100.0 ± 2.8 112.1 ± 4.7 105.1 ± 4.1
Ucp2 100.0 ± 6.0
a 55.5 ± 4.4
b 81.9 ± 4.6
c
1Values are means + SE, n = 29 or 30. Values with different superscript letter
are significantly different (P < 0.05).
Table 4 Plasma cytokines in diet induced obese mice fed
0.5% Ca (Control), 1.5% Ca (High-Ca), or 1.5% Ca +
nonfat dry milk (High-Ca + NFDM)
1
Diet
Cytokine Control High-Ca High-Ca + NFDM
ng/L
IL-6 2.7 ± 0.5 4.1 ± 1.1 1.6 ± 0.3*
IL-10 3.7 ± 3.3 6.4 ± 4.4 3.9 ± 2.5
IL-12(p70) 4.3 ± 1.7 12.9 ± 4.2 7.9 ± 4.5
MCP-1 16.1 ± 2.5 16.1 ± 3.7 9.6 ± 3.9
TNFa 3.2 ± 0.2 3.0 ± 0.2 3.8 ± 0.9
IL-15 38.6 ± 6.2 48.2 ± 11.4 70.8 ± 22.7
1Values are means + SE, n = 15. *P < 0.05 compared to mice fed high-Ca.
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Consistent with previous reports [4,6,7,9], we showed
reduced body weight and adiposity upon feeding a NFDM
diet containing high Ca to high fat fed polygenic DIO
rodents. Reductions in body weight and adiposity were
accompanied by lower WAT inflammation and liver tri-
glycerides as well as improved glucose tolerance. However,
the data do not support the idea that high dietary Ca in
isolation provides protection against obesity and associated
inflammation since DIO mice fed a soy protein-based
high-Ca diet actually became more obese and displayed
higher WAT inflammation, compared to lower-Ca con-
trols or mice fed high-Ca in a NFDM matrix. This differs
from observations in high-Ca fed aP2-agouti transgenic
mice fed an obesity-promoting diet where increased diet-
ary Ca attenuated weight gain, adiposity, and WAT
inflammation [5,20,21,34]. Experimental variables that
may have contributed to these discrepancies include diet
composition, energy consumption, genetic variation, and
study duration.
In the present study, body weight gain was not signifi-
cantly different between control mice and mice fed high-Ca
when controlling for energy consumption as a covariate.
Thus, increased energy consumption can explain differ-
ences in body weight gain between these diet treatment
groups, whereas daily food intake was not different in aP2-
agouti transgenic mice fed an obesigenic diet containing
high Ca [5,20,21,34]. Similar to our results, 21 wk food con-
sumption was increased in DIO male C57BL/6J mice fed
high Ca in the context of a high fat diet (60% kcal as fat)
containing whey, and a modest non-significant increase
was observed in DIO mice fed a high Ca, casein-based diet
[6]. Mice fed a 43% fat, NFDM-based high-Ca diet did not
d i s p l a yad i f f e r e n c ei ne n e r g yi n t a k er e l a t i v et ol o wC a ,
casein controls [7]. Thus, results in polygenic DIO mouse
models are consistent in thata n i m a l sf e dah i g h - C ad i e t
containing NFDM or whey protein display reduced body
weight gain and adiposity despite increased or unchanged
energy intakes. Protein source, and not Ca level, primarily
contributed to body composition differences in DIO rats
fed differing levels of Ca in the context of different dairy
protein sources (NFDM, whey, or casein) [35]. These obser-
vations indicate that non-Ca components derived from
dairy mainly drive adiposity reduction in polygenic DIO
rodents.
Suppression of circulating calcitriol via increased Ca
intake has been proposed as a primary mechanism for the
anti-obesity and anti-inflammatory properties of high diet-
ary Ca [22]. There is evidence that mice lacking the
nuclear vitamin D receptor or enzyme required to gener-
ate calcitriol have reduced adiposity, lower serum leptin,
and increased food intake [36]. Reduced adiposity in aP2-
agouti transgenic mice fed obesigenic high-Ca diets was
associated with reductions in blood calcitriol [20,21].
However, we observed that adiposity and body weight out-
comes in DIO mice fed high-Ca in isolation and in high-
Ca + NFDM showed no relation to differences in plasma
calcitriol, indicating that changes in calcitriol are not suffi-
cient to explain differences in body weight and adiposity
in this model.
Mice that consumed high-Ca in a soy protein-based
diet demonstrated increased feed efficiency, in contrast
to a lower feed efficiency in mice fed high-Ca + NFDM.
These results could emanate from diet-related differences
in gut energy uptake and/or tissue thermogenesis. There
was in fact increased net uptake of energy across the gut
in mice fed the soy-based high-Ca diet. An observed
increase in fecal energy loss in high-Ca + NFDM fed
mice cannot explain their reduced feed efficiency, since
increased energy intake in this group negated any differ-
ence in metabolizable energy compared to controls. With
respect to thermogenesis, reduced feed efficiency in mice
fed high-Ca + NFDM was not accompanied by increased
BAT UCP1 protein expression. Since UCP1 expression is


















































































Figure 4 Relative mRNA levels of CD68 (A) and CD11d (B) in RP-
WAT are significantly correlated to body weight in DIO mice fed
0.5% Ca (Controls, r = 0.62), 1.5% Ca (High-Ca; r =0 . 7 6 ) ,o r1 . 5 %
Ca + nonfat dry milk (High-Ca + NFDM; r =0 . 6 3 ) ,n =2 9( C o n t r o l )
or 30/treatment. P-values apply to all correlations within each panel.
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pretation is that in the high-Ca + NFDM mice enhanced
BAT thermogenesis did not contribute to the anti-obesity
effects of this diet. Alternatively, BAT UCP1 expression
was maintained at control levels despite lower body
weight in the high-Ca + NFDM mice, so another inter-
pretation is that this diet resulted in relative retention of
BAT thermogenic potential. The increased BAT size and
UCP1 protein expression in obese mice fed high-Ca was
reminiscent of that seen in cafeteria fed rats [37], and
this might be explained teleologically as a physiological
adaptation to overnutrition. Additional studies of ther-
mogenesis-related pathwaysi nm u s c l ea n do t h e rt i s s u e s
are warranted to clarify the mechanisms underpinning
reduced feed efficiency in high-Ca + NFDM fed mice.
The influence of calcitriol on WAT and muscle expres-
sion of IL-15 has been proposed to alter energy metabo-
lism, with expression increased upon feeding high-Ca
[20,26]. Increased IL-15 secretion has also been hypothe-
sized to discourage lipid accumulation [20,38]. In our
studies, WAT IL-15 gene expression was actually
decreased in mice fed high-Ca compared to controls (a
relationship held constant even after controlling body
weight gain), and there were no significant differences in
plasma IL-15 across diets. Thus, in polygenic DIO mice,
differences in adiposity and feed efficiency were not asso-
ciated with diet-related changes in WAT IL-15 expres-
sion or circulating IL-15 concentrations.
Non-Ca bioactive components of dairy thought to con-
tribute to the anti-obesity effects of NFDM may be derived
primarily from the whey protein fraction [22]. Supplemen-
tation with whey protein isolate reduced adiposity and
increased energy expenditure in high fat fed mice [39].
Whey protein is a rich dietary source of branched chain
amino acids (BCAA), which could in theory contribute to
activation of thermogenesis. Leucine or whey protein iso-
late supplementation of drinking water increased energy
expenditure and reduced diet induced obesity in mice
without reducing energy intake [39,40]. Leucine when pro-
vided to muscle cell cultures increased energy consump-
tion and indices of mitochondrial biogenesis (e.g., PGC-1
expression, mitochondrial mass), hypothesized to result
from activation of mammalian target of rapamycin com-
plex 1 (mTORC1) [41,42] or indirectly through anaplerosis
[43]. Whether BCAA derived from the NFDM diet contri-
butes to metabolic outcomes requires further experimental
validation. Notably, milk proteins also possess bioactive
peptides that have ACE-inhibitory properties [44], and the
ACE product angiotensin II enhances adipocyte lipid sto-
rage, promotes inflammation via activation of the NFB
pathway, and stimulates ROS-mediated insulin resistance
[45].
Chronic inflammation of WAT, hallmarked by macro-
phage accumulation, contributes to obesity-associated
morbidities. Since calcitriol evokes a pro-inflammatory
response in both adipocytes and macrophages, and
enhances pro-inflammatory mediators in co-cultures of
both cell types in vitro [19], high dietary Ca suppression
of plasma calcitriol may have anti-inflammatory proper-
ties [20]. High dietary Ca both with and without dairy
reduced WAT and systemic inflammation compared to
low dietary Ca in aP2-agouti transgenic obese mice [21].
However, interpretations of these observations are con-
founded by reduced adiposity resulting from high dietary
Ca intake in that model. We found that WAT expression
of the pan-macrophage surface antigen CD68 correlated
positively with body weight regardless of diet. WAT
mRNA abundance for CD11d (an immune cell-specific
cell adhesion molecule expressed on a subset of macro-
phages [46]) also correlated with body weight, but for any
given weight was lower in NDFM-fed mice compared to
controls or high-Ca fed mice. Diet-associated differences
in most WAT inflammatory gene markers were lost
when controlling for body weight. These results conclu-
sively demonstrate that dietary Ca and/or NFDM effects
on WAT inflammation in DIO mice are primarily
explained by their impact on weight. In DIO mice fed dif-
ferent levels of fat (10%, 45%, and 60%), WAT macro-
phage marker expression correlated with body weight
and adiposity in lean-to-moderately obese animals [24],
similar to our current observations. These findings sup-
port the hypothesis that WAT macrophage infiltration
(at least for some macrophage sub-types) is closely yoked
to expansion of energy storage capacity during modest
caloric overnutrition, possibly as a mechanism for macro-
phage-mediated WAT extracellular matrix and vascular
remodeling to accommodate normal physiologic adipo-
cyte hypertrophy. Significant correlations between WAT
inflammatory markers and body weight was reported
when looking across disparate mouse obesity models
[15], and positive correlations were observed between %
CD14+ cells in isolated stromal vascular cells from WAT
and BMI in normal weight to obese humans [47,48].
Shaul et al. [49] have also considered a remodeling func-
tion based on dynamic M2-like macrophage phenotypes
in rodents. The observations that WAT macrophage
marker expression closely tracks body weight (at least in
lean to moderate obese states) highlights a need to
understand weight-specific immune signals and macro-
phage functions during normal, non-pathological WAT
expansion and contraction.
Conclusion
Mechanisms underlying the anti-obesity and/or anti-
inflammatory properties of dairy components remain to
be clarified. A primary role for increased dietary Ca is
not supported in the current DIO mouse model since
high Ca fed in a soy protein-based diet did not reduce,
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inflammation in stark contrast to animals fed high Ca in
a NFDM-based matrix. Further deconvolution of the
complex components of dairy foods is required in order
to identify those specific factors that influence energy
balance and inflammation.
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